PMID- 19115689
OWN - NLM
STAT- MEDLINE
DCOM- 20090414
LR  - 20200929
IS  - 0392-2936 (Print)
IS  - 0392-2936 (Linking)
VI  - 29
IP  - 6
DP  - 2008
TI  - Preoperative transforming growth factor-beta 1 (TGF-beta 1) plasma levels in 
      operable breast cancer patients.
PG  - 613-6
AB  - OBJECTIVES: The aim of this project was to search for new risk prognostic markers 
      in the early stage of breast cancer. We tested preoperative plasma transforming 
      growth factor - beta 1 (TGF- beta 1) levels in patients with operable breast 
      cancer. Correlation with traditional prognostic markers and with 
      positivity/negativity sentinel lymph node was evaluated. MATERIALS AND METHODS: 
      Between 2003 and 2005, 36 patients with operable breast cancer (T1-2, N0-1, M0) 
      with positive or negative sentinel lymph nodes were evaluated for their plasma 
      TGF-beta 1. Twenty-seven healthy individuals (9 premenopausal and 18 
      postmenopausal) served as controls. Patients were evaluated for the traditional 
      prognostic markers including tumor characteristics, positivity and negativity of 
      sentinel lymph node, TNM, tumor grade, expression of tumor markers CA 15-3 and 
      CEA, hormonal status (pre- or postmenopausal patients, estrogen and progesteron 
      receptor expression), ERB and p53 expression. Predictive value of TGF-beta 1 
      level and correlation with either of the assessed parameters was tested by one 
      way ANOVA analysis. RESULTS: Measurements of preoperative plasma TGF-beta 1 
      levels in patients with operable breast cancer were significantly higher compared 
      with healthy individuals (median 15293 and 3983 pg/ml p < 0.0001). TGF-beta 1 
      level in plasma of patients with a positive sentinel lymph node was significantly 
      higher than in patients with negative sentinel lymph nodes (high vs low, median 
      18,9 and 14,5 ng/ml, respectively, p = 0.05). CONCLUSION: The determination of 
      TGF-beta 1 status might help to identify a high-risk population early in tumor 
      progression, for which a more appropriate therapy should be established. In the 
      node-negative population, the up-regulation of TGF-beta 1 might constitute an 
      early event that promotes further progression of breast tumors.
FAU - Chod, J
AU  - Chod J
AD  - Department of Obstetrics and Gynecology, 2" Medical Faculty, Charles University, 
      Prague, Czechslovakia. jiri.chod@seznam.cz
FAU - Zavadova, E
AU  - Zavadova E
FAU - Halaska, M J
AU  - Halaska MJ
FAU - Strnad, P
AU  - Strnad P
FAU - Fucikova, T
AU  - Fucikova T
FAU - Rob, L
AU  - Rob L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Singapore
TA  - Eur J Gynaecol Oncol
JT  - European journal of gynaecological oncology
JID - 8100357
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Transforming Growth Factor beta1)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/*blood
MH  - Breast Neoplasms/*blood/pathology/surgery
MH  - Carcinoma, Ductal, Breast/*blood/pathology/surgery
MH  - Carcinoma, Lobular/*blood/pathology/surgery
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Risk Factors
MH  - Sentinel Lymph Node Biopsy
MH  - Transforming Growth Factor beta1/*blood
EDAT- 2009/01/01 09:00
MHDA- 2009/04/15 09:00
CRDT- 2009/01/01 09:00
PHST- 2009/01/01 09:00 [entrez]
PHST- 2009/01/01 09:00 [pubmed]
PHST- 2009/04/15 09:00 [medline]
PST - ppublish
SO  - Eur J Gynaecol Oncol. 2008;29(6):613-6.